Franck Le Deu (@fle864) profile picture

Founder and Managing Partner of KerZheng Ventures. Venture Partner Aulis Capital Sr Partner Emeritus McKinsey. Based in Hong Kong for 20 yrs. Views are my own.

Hong Kong
Joined May 2009
Photo by Franck Le Deu (@fle864)Photo by Franck Le Deu (@fle864)Photo by Franck Le Deu (@fle864)Photo by Franck Le Deu (@fle864)
Franck Le Deu retweeted
I recently had the opportunity to discuss BeOne’s global capabilities on Cambridge Associates’ Unseen Upside podcast, including why we invested in building our own global development “superhighway” and what I’ve learned about the power of scientific collaboration across borders. I hope you’ll listen to the conversation: ow.ly/uFgv5105csv #UnseenUpside #Oncology #Innovation
1
1
2
225
Franck Le Deu retweeted
For Bloomberg News Big Take, a deep dive on how biotech startups and pharma giants are increasingly taking trials to China early — and the new and complex challenges they pose. with @ashleighfurlong @fabiennekatrin and team: bloomberg.com/news/features/…
6
14
2,156
Franck Le Deu retweeted
The U.S. Treasury is proposing new restrictions on investments in Chinese biotech, but traditional pharma licensing deals would largely be spared. Equity investments and certain partnerships could face significant hurdles. fiercebiotech.com/biotech/tr…
1
4
1
14
3,606
Europe’s narrow path between the U.S. and China in biotech biocentury.com/article/65981… I wrote this three months ago for BioCentury. It feels increasingly relevant, between the China 15 FYP for Biopharma, the letter from US CEOs asking Congress not to block China deals, and the letter from European Boards asking European leaders to wake up, or else…
1
110
Franck Le Deu retweeted
« Il faut une première à tout et il faut une dernière pour se souvenir, une dernière, juste pour lui. ❤️ » Merci à @ligue1plus pour LES ÉMOTIONS sur cette bande-annonce de Brest-PSG avec un hommage pour Éric Roy 🇫🇷. 🥹🕊️
7
308
7
3,218
153,429
Franck Le Deu retweeted
Listen to Episode 44 of @BioVentureVoiCe video podcast w/ Adam Koppel, Partner at @BainCapital. Adam discusses the evolution of biotech investing from the early days of crossover investing to company creation w/ pharma assets and the current strategies out of Bain Capital's Life Sciences private equity fund. The full video is here on @BiotechTV (and also on Spotify and Apple Podcasts): biotechtv.com/post/adam-kopp…
𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬: @BainCapital's Adam Koppel discusses both public and private equity investing in biotech, and how the sector has changed over his years in the space. Full video: biotechtv.com/post/adam-kopp…
1
3
1
24
3,525
Franck Le Deu retweeted
Thoughtful and detailed comments by Alexis Borisy on the China debate, which he has lived from many angles including EQRx, at our conference this week.
𝐔.𝐒. 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐒𝐮𝐦𝐦𝐢𝐭: Alexis Borisy shares his take on one of today's biggest debates in biotech, the impact of China on the U.S. biotech sector.
2
5
1
29
9,531
Franck Le Deu retweeted
Hengrui rising: Frank Jiang on building a global biotech. On The BioCentury Show, Jiang discusses Hengrui’s R&D scale, global ambitions, and what its GSK and BMS alliances reveal about the next phase of China-originated innovation. buff.ly/soem45G
5
5
817
Franck Le Deu retweeted
Europe's narrow path between the U.S. and China: Europe has an opening to become biotech's third pole, says Franck Le Deu in a BioCentury Guest Commentary, but only if it engages China while anchoring IP, manufacturing, development at home (open access): biocentury.com/article/65981…
1
2
188
❤️
14
534
7
4,752
110,215
Franck Le Deu retweeted
A écouter. Absolument passionnant pour quiconque s’intéresse à la démographie au moment où nous vivons un phénomène mondial sans précédent : Why birth rates are falling everywhere all at once | FT youtu.be/6lFXmDk-tps?is=FaqR… via @YouTube
25
4
100
67,345
Franck Le Deu retweeted
My new essay "A Biopharmaceutical Superpower: China’s Rise, Its Limits, and What Comes Next": China’s biopharma revolution is real: once a generics & API giant, it now controls ~80% of global API intermediates, nearly all KSMs for key U.S. drugs, and is closing the gap on innovative pipelines. Record licensing deals topped $135B last year—Pfizer alone paid $1.25B for a Chinese bispecific. 1/3 cirsd.org/horizon-article/a-…
2
5
16
3,294
Franck Le Deu retweeted
In support of a multipolar biopharma world. Why a strong U.S. sector can still thrive next to a stronger China: a BioCentury Guest Commentary by Franck Le Deu buff.ly/5BWbKml
1
2
487